

**REMARKS**

Applicants appreciate the positive outcome of the Pre-Appeal Brief review and the subsequent Notice of Allowance. According to 37 CFR §1.312, an amendment filed pursuant to this section may be entered after allowance on the recommendation of the primary examiner without withdrawing the application from issue.

Claims 22, 43 and 64 have been amended above to change the plurality “fluorescence signals” to the singular “fluorescent signal” in order to create antecedent basis for this phrase. This issue was raised in the Office Action dated January 6, 2006 (page 4), was mentioned in the Pre-Appeal Brief Request (page 5), but was not resolved in the Pre-Appeal Brief review process. Claim 22 has also been amended to correct a typographical error through which the appropriate parentheses around the acronym CNG were inadvertently omitted. Claim 64 has also been amended to indicate that “GPCR” is an acronym for “G protein-coupled receptor.”

No new matter is believed to be added by entry of these amendments.


Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-1283. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. 1.136(a)(3).

Respectfully submitted,

**COOLEY GODWARD LLP**

Dated: July 26, 2006  
COOLEY GODWARD LLP  
**Customer No. 58249**  
875 15<sup>th</sup> Street, NW, Ste. 800  
Washington, D.C. 20005  
Tel: 202-842-7800

By:

  
Bonnie Weiss McLeod  
Registration No. 43,255